Immix Biopharma, Inc. · NASDAQ:IMMX
Immix Biopharma — 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024
17 slides from Immix Biopharma's conference presentation, Dec 10, 2024
Slide 1: NXC-201 Clinical Data Update and Outlook at ASH 2024 in Relapsed/Refractory AL Amyloidosis
NXC-201 Clinical Data Update and Outlook at ASH 2024 in Relapsed/Refractory AL Amyloidosis 4:30pm ET Tue Dec 10
Slide 2: Disclaimer: Forward Looking Statements & Market Data
Disclaimer: Forward Looking Statements & Market Data This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.
Slide 3: Attendees
Attendees • Ilya Rachman, MD PhD, Chief Executive Officer • Gabriel Morris, Chief Financial Officer • Moderated by Michael Moyer, Managing Director, LifeSci Advisors Agenda: Following formal remarks, there will be a question-and-answer session Formal remarks include: 1) review of ex-US NEXICART-1 AS
Slide 4: This Is Pre-Existing Heart Failure in AL Amyloidosis
This Is Pre-Existing Heart Failure in AL Amyloidosis d PRE-EXISTING HEART FAILURE CAUSES PHYSICALLY IRREVERSIBLE DISTORTION OF HEART STRUCTURE, SHAPE AND SIZE Pre-existing heart failure Preserved heart function 4 -
Slide 5: 75% (12/16) Complete Response Rate. No ICANS Neurotoxicity (NEXICART-1)
75% (12/16) Complete Response Rate. No ICANS Neurotoxicity (NEXICART-1) • Patient Characteristics: • 16 patients dosed (ASH 2024 update: 3 new patients and longer follow-up, median 8.4 months (range 4-31.5) • 81% (13/16), 69% (11/16), 38% (6/16), had pre-existing Heart, Kidney, Liver involvement, re
Slide 6: NXC-201 Produces Rapid and Deep Responses <2 Weeks After Dosing
NXC-201 Produces Rapid and Deep Responses <2 Weeks After Dosing NXC-201 Dosing dFLC (mg/L) Time since NXC-201 Infusion (days) (Each line represents 1 patient clinical data readout after NXC-201) Note: Data cut-off as of December 9, 2024. E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antig
Slide 7: 6 patients had pre-existing heart failure; 10 patients had preserved heart function
6 patients had pre-existing heart failure; 10 patients had preserved heart function d d PRE-EXISTING HEART FAILURE CAUSES PHYSICALLY IRREVERSIBLE DISTORTION OF HEART STRUCTURE, SHAPE AND SIZE NEXICART-1 Preserved heart function Pre-existing heart failure Median (range) Patient # 1 2 3 4 5 6 7 8 9 10
Slide 8: NXC-201 Produces Durable Complete Responses in Patients with Preserved Heart Function
NXC-201 Produces Durable Complete Responses in Patients with Preserved Heart Function Duration of response (ASH 2024) Stage 1/2 Ongoing response Stage 1/2 Cardiac death in CR/VGPR Stage 1/2 Cardiac death while in PD Stage 1/2/3 Preserved Stage 1/2/3 Discontinued heart function Target For U.S. AL Amy
Slide 9: 75% Complete Response Rate is the FDA Regulatory Endpoint
75% Complete Response Rate is the FDA Regulatory Endpoint NEXICART-1 Preserved heart function Pre-existing heart failure Patient # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 CART cells infused 150 450 800 450 800 800 800 800 800 800 800 800 800 800 800 800 (x106) Best hematologic CR CR CR CR CR VGPR PR
Slide 10: Favorable Tolerability: No Neurotoxicity of Any Grade. Short Duration CRS
Favorable Tolerability: No Neurotoxicity of Any Grade. Short Duration CRS Total Total Grade 3-4 ICANS and other neurotoxicity, Hematological toxicity, n/N 0/16 (0) n/N (%) Anemia 12/16 5/16 Treatment-related mortality, n/N (%) 0/16 (0) Thrombocytopenia 9/16 0/16 CRS, n/N (%) Neutropenia 12/16 10/16
Slide 11: Rapid Responses to NXC-201 in Relapsed/Refractory AL Amyloidosis Patients were Observed
Rapid Responses to NXC-201 in Relapsed/Refractory AL Amyloidosis Patients were Observed “An early and deep hematologic response has been found to lead to significantly prolonged survival” – Vaishali Sanchorawala, M.D. Professor, Hematology and Oncology Director, Amyloidosis Center at Boston Universi
Slide 12: NEXICART-2: Ongoing US Study
NEXICART-2: Ongoing US Study
Slide 13: NEXICART-2 US Relapsed/Refractory AL Amyloidosis Trial (NCT06097832)
NEXICART-2 US Relapsed/Refractory AL Amyloidosis Trial (NCT06097832) NEXICART-2 NXC-201 US TRIAL INITIATED IN MID-2024 Study design Status • Open-label, single-arm Phase 1b/2 study • Lead site Memorial Sloan Kettering and other US sites started mid-2024 • n=40 patients (majority of which expected to
Slide 14: Single-arm potentially pivotal NEXICART-2 trial designed considering NEXICART-1 and precedents in AL
Single-arm potentially pivotal NEXICART-2 trial designed considering NEXCIART-1 and precedents in AL 2021 daratumumab (DARZALEX) FDA Approval NXC-201 NEXICART-2 Line of Therapy Newly Diagnosed Relapsed/Refractory Standard of Care (SoC) 3-drug combination: Cyclophosphamide, ✓ None (no FDA approvals)
Slide 15: Q&A
Q&A Moderator: Michael Moyer, Managing Director LifeSci Advisors
Slide 16: NXC-201 Clinical Data Update and Outlook at ASH 2024 in Relapsed/Refractory AL Amyloidosis
NXC-201 Clinical Data Update and Outlook at ASH 2024 in Relapsed/Refractory AL Amyloidosis 4:30pm ET Tue Dec 10
Slide 17: Complete Hematologic Response is correlated with longer survival
Complete Hematologic Response is correlated with longer survival COMPLETE HEMATOLOGIC RESPONSE WAS PRIMARY ENDPOINT IN 2021 DARATUMUMAB APPROVAL STUDY AND ONGOING NEXICART-2 TRIAL Complete Hematologic Response (CR) associated with improved survival in AL 2x survival at 48 months for CR vs PR • Compl